Immix Biopharma (NASDAQ:IMMX – Get Free Report) is one of 968 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Immix Biopharma to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings.
Analyst Ratings
This is a summary of current ratings and target prices for Immix Biopharma and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immix Biopharma | 0 | 0 | 3 | 0 | 3.00 |
| Immix Biopharma Competitors | 5171 | 16702 | 42148 | 805 | 2.60 |
Immix Biopharma currently has a consensus target price of $14.00, suggesting a potential upside of 308.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 83.51%. Given Immix Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe Immix Biopharma is more favorable than its peers.
Volatility and Risk
Profitability
This table compares Immix Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immix Biopharma | N/A | -83.12% | -74.60% |
| Immix Biopharma Competitors | -2,333.45% | -329.04% | -34.49% |
Earnings and Valuation
This table compares Immix Biopharma and its peers top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Immix Biopharma | N/A | -$8.23 million | -4.29 |
| Immix Biopharma Competitors | $1.80 billion | $229.66 million | -4.81 |
Immix Biopharma’s peers have higher revenue and earnings than Immix Biopharma. Immix Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
4.0% of Immix Biopharma shares are owned by institutional investors. Comparatively, 40.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 55.9% of Immix Biopharma shares are owned by company insiders. Comparatively, 15.1% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Immix Biopharma beats its peers on 7 of the 13 factors compared.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
